- Home
- ADAP vs HOTH Comparison
ADAP vs HOTH Comparison
Compare ADAP & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- HOTH
- Stock Information
- Founded
- ADAP 2008
- HOTH 2017
- Country
- ADAP United Kingdom
- HOTH United States
- Employees
- ADAP N/A
- HOTH N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- HOTH Health Care
- Exchange
- ADAP Nasdaq
- HOTH Nasdaq
- Market Cap
- ADAP 21.3M
- HOTH 19.0M
- IPO Year
- ADAP 2015
- HOTH 2019
- Fundamental
- Price
- ADAP $0.08
- HOTH $1.33
- Analyst Decision
- ADAP Hold
- HOTH Strong Buy
- Analyst Count
- ADAP 6
- HOTH 2
- Target Price
- ADAP $1.02
- HOTH $4.50
- AVG Volume (30 Days)
- ADAP 106.3M
- HOTH 1.1M
- Earning Date
- ADAP 11-12-2025
- HOTH 11-11-2025
- Dividend Yield
- ADAP N/A
- HOTH N/A
- EPS Growth
- ADAP N/A
- HOTH N/A
- EPS
- ADAP N/A
- HOTH N/A
- Revenue
- ADAP $65,084,999.00
- HOTH N/A
- Revenue This Year
- ADAP N/A
- HOTH N/A
- Revenue Next Year
- ADAP $24.70
- HOTH N/A
- P/E Ratio
- ADAP N/A
- HOTH N/A
- Revenue Growth
- ADAP N/A
- HOTH N/A
- 52 Week Low
- ADAP $0.04
- HOTH $0.66
- 52 Week High
- ADAP $0.86
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- ADAP 41.40
- HOTH 36.58
- Support Level
- ADAP $0.04
- HOTH $1.45
- Resistance Level
- ADAP $0.24
- HOTH $1.52
- Average True Range (ATR)
- ADAP 0.04
- HOTH 0.12
- MACD
- ADAP -0.01
- HOTH -0.03
- Stochastic Oscillator
- ADAP 15.65
- HOTH 0.00
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).